Specify a stock or a cryptocurrency in the search bar to get a summary
Elicio Therapeutics Inc.
ELTXElicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node"targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts. Address: 451 D Street, Boston, MA, United States, 02210
Analytics
WallStreet Target Price
9.5 USDP/E ratio
5.5217Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ELTX
Dividend Analytics ELTX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ELTX
Stock Valuation ELTX
Financials ELTX
Results | 2019 | Dynamics |